Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000273 · ClinicalTrials.gov registry record · Phase 2
A Laboratory Model for Heroin Abuse Medications - 8
A Phase 2 study of Substance-Related Disorders and Opioid-Related Disorders, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
- 2
- Study locations
NCT00000273: Completed Phase 2 study of Substance-Related Disorders and Opioid-Related Disorders, sponsored by New York State Psychiatric Institute.
NCT00000273 is a Phase 2 study of Substance-Related Disorders and Opioid-Related Disorders that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 8 participants, below the 1,521-participant average among 58 other Substance-Related Disorders trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00000273, a Phase 2 study of Substance-Related Disorders and Opioid-Related Disorders, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate the effects of treatment medications (methadone, buprenorphine, LAAM, naltrexone, naltrexone microcapsules, and methoclocinnamox) on I.V. and smoked heroin self-administration."
Primary Outcome
All of the participants received all of the drugs tested; drugs and doses were administered in non-systematic order. Participants were instructed to choose between the dose that they had received during the sample session or another reward..
Conditions Studied
Interventions
- DRUG opiates
Study Locations (2)
New York
- Columbia University - New York
- New York State Psychiatric Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 1995-08 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
What the finished NCT00000273 record still lists
NCT00000273 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 1,521-participant average among 58 other Substance-Related Disorders trials with a reported enrollment target (99% lower).
The record links to 3 conditions, with Substance-Related Disorders appearing as the primary indexed condition, and to 1 intervention - of which opiates is the first listed.
NCT00000273 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00000273 about?
NCT00000273 is a clinical study titled "A Laboratory Model for Heroin Abuse Medications - 8". The purpose of this study is to evaluate the effects of treatment medications (methadone, buprenorphine, LAAM, naltrexone, naltrexone microcapsules, and methoclocinnamox) on I.V. and smoked heroin self-administration."
What is the current status of trial NCT00000273?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 1995-08. Estimated completion is 2005-11.
What conditions does trial NCT00000273 study?
This clinical trial studies the following conditions: Substance-Related Disorders, Opioid-Related Disorders, Heroin Dependence.
What interventions are being tested in trial NCT00000273?
The interventions under investigation include: opiates (DRUG).
Who is sponsoring clinical trial NCT00000273?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00000273 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Substance-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00000273's enrollment target sits among peer trials
8 59th of 58 the lowest of 58 other Substance-Related Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Substance-Related Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder
RECRUITING · Phase 2
-
GLP-1R Agonist Treatment for Opioid Use Disorder
RECRUITING · Phase 2
-
Cold Water Immersion Modulates Reinforcing Effects of Nitrous Oxide - 2
COMPLETED · Phase 2
-
The Efficacy of Methadyl Acetate (LAAM) and Contingency Management Procedures for Treating Dual Opioid and Cocaine Abuse - 1
COMPLETED · Phase 2
-
Buprenorphine Maintenance for Opiate Dependence - 6
COMPLETED · Phase 2
-
Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia